Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Suspected heparin-induced thrombocytopaenia in pulmonary thromboendarterectomy: retrospective cohort.
Interdiscip Cardiovasc Thorac Surg
December 2024
Department of Thoracic Surgery and Heart-Lung Transplantation, Paris-Saclay University, Marie-Lannelongue Hospital, Le Plessis-Robinson, France.
Objectives: Heparin is given for anticoagulation during and after pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension. Our objective was to add to the limited data available on the incidence, management and outcomes of suspected heparin-induced thrombocytopaenia after pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension.
Methods: This retrospective single-centre study included consecutive patients with suspected heparin-induced thrombocytopaenia after pulmonary thromboendarterectomy done in 2005-2018.
In-Hospital and Midterm Outcomes of Lead Extraction: A Single-Center Clinical Study.
J Tehran Heart Cent
January 2024
Department of Cardiac Electrophysiology, Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Background: The rate of lead extraction has steadily increased alongside the extensive use of cardiovascular implantable electronic devices. Data on the complications and safety of this challenging procedure are limited. We investigated inhospital and midterm outcomes following lead extraction.
View Article and Find Full Text PDFHeparin-induced thrombocytopenia during anticoagulation therapy for COVID-19-related pulmonary embolism: A case report.
Medicine (Baltimore)
December 2024
Civil Aviation General Hospital, Beijing, China.
Rationale: One of the main characteristics of COVID-19 is the high incidence of venous thromboembolism, particularly pulmonary embolism. Anticoagulation therapy is the primary treatment for pulmonary embolism. Heparin-induced thrombocytopenia (HIT) is an antibody-mediated adverse reaction to heparin that occurs during its use of heparin drugs.
View Article and Find Full Text PDFEvaluating the Compliance to 24-Hour Venous Thromboembolism Risk Re-assessment Following Orthopaedic Surgery at a Tertiary Center: A Closed-Loop Clinical Audit.
Cureus
November 2024
Anesthesia and Critical Care, Royal National Orthopaedic Hospital, London, GBR.
Introduction Venous thromboembolism (VTE) is a preventable cause of patient morbidity and mortality among hospitalised patients. VTE events have a high incidence among orthopaedic patients, who routinely receive chemical thromboprophylaxis in the form of heparin, warfarin, antiplatelet agents or direct oral anticoagulants. These can be associated with adverse events, most commonly bleeding or heparin-induced thrombocytopenia.
View Article and Find Full Text PDFHeparin-induced thrombocytopenia-II in hospitalized patients with surgery or deep vein thrombosis.
Am J Blood Res
October 2024
Nerophysiology Research Center, Hamadan University of Medical Sciences Hamadan, Iran.
Article Synopsis
- This study examines heparin-induced thrombocytopenia (HIT-II), a serious complication in hospitalized patients receiving heparin, particularly after surgery or for deep vein thrombosis (DVT).
- The research involved 754 patients and found a HIT-II incidence rate of 4.50%, with higher occurrences in older adults and females, along with increased thrombosis rates and elevated levels of various inflammatory markers.
- The study concludes that platelet activation in HIT-II patients contributes to more thrombosis formation, longer hospital stays, and higher mortality rates compared to non-HIT patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!